These results underscore the pivotal role of the RANK-receptor activator of NF-κB ligand (RANKL) axis in tumour growth and immune regulation, supporting the use of triple-targeting therapy and suggesting enhanced benefits with the inclusion of ICIs to potentially overcome therapeutic resistance in HER2<sup>+</sup> BC. The gene discussed is ERBB2; the disease is breast cancer.